E3 PreliminaryPreliminaryPEM unclearCross-SectionalPeer-reviewedMachine draft
Clinical features and IgG subclass distribution of anti-p80 coilin antibodies.
Onouchi, H, Muro, Y, Tomita, Y · Journal of autoimmunity · 1999 · DOI
Quick Summary
Researchers tested blood samples from 365 Japanese patients and found 11 with unusual antibodies called anti-p80-coilin antibodies. All 11 were young women experiencing fatigue, joint pain, headaches, and other symptoms similar to ME/CFS. The study found that these antibodies come in different types, and one type (IgG2) might be a marker for autoimmune disease.
Why It Matters
This study identifies anti-p80-coilin antibodies in young women presenting with CFS-like symptoms, suggesting a potential autoimmune biomarker for this patient population. Understanding antibody signatures in ME/CFS may help distinguish this condition from other rheumatic diseases and could guide future diagnostic and therapeutic approaches.
Observed Findings
- All 11 anti-p80-coilin seropositive patients were female, with nine in their twenties
- Most seropositive patients reported general fatigue, arthralgia, headaches, dysmenorrhea, lymph node swelling, and/or low-grade fever
- Patients' sera showed predominant IgG1 anti-p80-coilin antibodies, with five sera containing concomitant IgG2
- Low complement levels were observed in the seropositive patients
- Only one seropositive patient fulfilled diagnostic criteria for CFS; two had diagnosed rheumatic disease (systemic scleroderma and Sjögren's syndrome)
Inferred Conclusions
- Anti-p80-coilin antibodies may be a marker for a subgroup of young females with systemic autoimmune features and CFS-like symptoms
- IgG2 anti-p80-coilin antibodies may be a specific marker for differentiated systemic autoimmune disease rather than undifferentiated illness
- The predominance of young females with these antibodies and nonspecific symptoms suggests a potentially distinct immunological phenotype
Remaining Questions
- Are anti-p80-coilin antibodies present in larger cohorts of ME/CFS patients meeting strict diagnostic criteria?
- Does the presence or absence of anti-p80-coilin antibodies predict clinical outcome or treatment response in CFS?
What This Study Does Not Prove
This study does not establish that anti-p80-coilin antibodies cause ME/CFS or are diagnostic of it, as only one patient fulfilled ME/CFS criteria. The cross-sectional design cannot determine whether these antibodies precede, accompany, or result from illness. The small sample size and lack of healthy controls limit generalizability beyond the Japanese population studied.
Tags
Symptom:PainFatigue
Biomarker:AutoantibodiesBlood Biomarker
Method Flag:Weak Case DefinitionNo ControlsSmall SampleExploratory Only
Metadata
- DOI
- 10.1006/jaut.1999.0318
- PMID
- 10479391
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →